Abstract
Crohn’s disease (CD) is a chronic, disabling, progressive and destructive disease. The general goal of conventional step-up strategy in CD treatment is to treat and control symptoms. This strategy did not change the disease course and is now being replaced with a treat-to-target approach. Achieving deep remission (clinical remission and absence of mucosal ulcerations) is the target in CD in 2014. Inducing and maintaining deep remission is needed to prevent long-term outcomes such as bowel damage and disability in CD. Diagnostic delay is a common issue in CD and is associated with an increased risk of bowel damage over time. Identification of poor prognostic factors, risk stratification together with the development of “red flags” may result in early intervention with disease-modifying agents such as anti-TNF agents with the final aim of preventing overtreatment and avoiding undertreatment. Similar to rheumatoid arthritis, by catching the therapeutic window of opportunity in early CD and achieving deep remission, this could be the best way to change disease course (hospitalizations, surgeries, bowel damage, and disability) and patients’ life.
Keywords: Crohn’s disease, early disease, inflammatory bowel disease, therapy.
Current Drug Targets
Title:Catching the Therapeutic Window of Opportunity in Early Crohn`s Disease
Volume: 15 Issue: 11
Author(s): Silvio Danese, Gionata Fiorino, Carlos Fernandes and Laureal Peyrin-Biroulet
Affiliation:
Keywords: Crohn’s disease, early disease, inflammatory bowel disease, therapy.
Abstract: Crohn’s disease (CD) is a chronic, disabling, progressive and destructive disease. The general goal of conventional step-up strategy in CD treatment is to treat and control symptoms. This strategy did not change the disease course and is now being replaced with a treat-to-target approach. Achieving deep remission (clinical remission and absence of mucosal ulcerations) is the target in CD in 2014. Inducing and maintaining deep remission is needed to prevent long-term outcomes such as bowel damage and disability in CD. Diagnostic delay is a common issue in CD and is associated with an increased risk of bowel damage over time. Identification of poor prognostic factors, risk stratification together with the development of “red flags” may result in early intervention with disease-modifying agents such as anti-TNF agents with the final aim of preventing overtreatment and avoiding undertreatment. Similar to rheumatoid arthritis, by catching the therapeutic window of opportunity in early CD and achieving deep remission, this could be the best way to change disease course (hospitalizations, surgeries, bowel damage, and disability) and patients’ life.
Export Options
About this article
Cite this article as:
Danese Silvio, Fiorino Gionata, Fernandes Carlos and Peyrin-Biroulet Laureal, Catching the Therapeutic Window of Opportunity in Early Crohn`s Disease, Current Drug Targets 2014; 15 (11) . https://dx.doi.org/10.2174/1389450115666140908125738
DOI https://dx.doi.org/10.2174/1389450115666140908125738 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bhasma: Indian Perspective of Nanomedicinal Technology
Recent Patents on Nanomedicine Repetitive Transcranial Magnetic Stimulation to Treat Substance Use Disorders and Compulsive Behavior
CNS & Neurological Disorders - Drug Targets Withdrawal Notice: Mucoadhesive Microspheres: An Emerging Trends in Therapy of Diabetes Mellitus
Current Diabetes Reviews Emerging Therapies for Diabetic Neuropathy: A Clinical Overview
Current Diabetes Reviews Prostate Cancer Immunotherapy: An Evolving Field
Current Cancer Therapy Reviews Is Nitric Oxide Assuming a Janus-Face in The Central Nervous System?
Current Medicinal Chemistry Pulmonary Hypertension in the Critically Ill
Current Hypertension Reviews Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review
Current Respiratory Medicine Reviews Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology Emerging Trends in Endometriosis Treatment - Review
Current Women`s Health Reviews Molecular Diagnosis and Treatment of Multiple Endocrine Neoplasia Type 2B in Ethnic Han Chinese
Endocrine, Metabolic & Immune Disorders - Drug Targets Internet Addiction: A Systematic Review of Epidemiological Research for the Last Decade
Current Pharmaceutical Design Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology Imiquimod 5% Cream Use in Dermatology, Side Effects and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery The Effects of Placental Corticotrophin Releasing Hormone on the Physiology and Psychology of the Pregnant Woman
Current Women`s Health Reviews Oseltamivir Pharmacology in Young Children: A Commentary
Infectious Disorders - Drug Targets Mood Charting and Technology: New Approach to Monitoring Patients with Mood Disorders
Current Psychiatry Reviews The Tortuous Road to an Ideal CGRP Function Blocker for the Treatment of Migraine
Current Topics in Medicinal Chemistry Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
Current Molecular Pharmacology